Medindia

X

Erin M. Sullivan Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Reimbursement & Health Economics

Wednesday, October 8, 2008 General News J E 4
Advertisement
LEXINGTON, Mass., Oct. 7 Erin M. Sullivan, M.P.H., Ph.D.,a specialist in reimbursement, health economics, and health policy issues, hasjoined Abt Bio-Pharma Solutions, Inc. (ABS) as Senior Director, Reimbursementand Health Economics. Dr. Sullivan has more than 15 years of experience inindustry and consulting and has led and contributed to a broad spectrum ofsuccessful projects, providing expertise and insight in private payerstrategy, prospective and retrospective health economics studies, patientreported outcomes research, and registry and clinical trial study design andoperations.

"We are very pleased to welcome Erin as a member of our senior team," saidSteve Fosburg, President of ABS. "Our clients are increasingly faced with awide variety of challenges to product success and the bottom line, includingcompetitive pressures, generics/patent expiration, and unfavorablereimbursement/regulatory environments. Traditional approaches tend to be tooone-dimensional to effectively manage these complex issues, which is why somany sponsors prefer ABS' brand of integrated, cross-disciplinary solutions.Erin's diverse experience and wide-ranging skill set is a perfect match."

Prior to joining ABS, Dr. Sullivan was a Director of Health Economics andReimbursement at Boston Scientific Corporation. In this role, she led a teamof researchers in providing strategic guidance and implementing reimbursement,health economic, and health policy initiatives to support a $700 millionglobal business unit. Dr. Sullivan has also held research positions at TheLewin Group/Quintiles, Covance Health Economics and Outcomes Services, and theBeth Israel Hospital. Her work has been published in numerous peer-reviewedscientific healthcare journals including Pharmacoeconomics, Value in Health,Journal of Clinical Psychiatry, Arthritis Care and Research, and Urology.

Dr. Sullivan earned a Ph.D. in Health Services Research from the JohnsHopkins Bloomberg School of Public Health, a Master of Public Health from TheGeorge Washington University School of Hygiene and Public Health, and aBachelor of Science in Psychology from Vanderbilt University.

The ABS team has provided integrated strategic, research, andcommercialization services to the pharmaceutical, biotechnology, medicaldevice, and diagnostics industries for more than 20 years. The companyspecializes in demonstrating the value, safety, and efficacy of healthtechnologies through prospective studies such as registries as well as throughretrospective data analyses, models, and quantitative and qualitativeresearch. ABS teams of senior, seasoned staff help sponsors develop theirresearch agendas, successfully conduct their research programs, andcommunicate the results to internal and external audiences. Primary serviceofferings include registries and other late-phase clinical studies, healtheconomics and outcomes research, pricing and reimbursement, strategiccommercialization services, and biometrics. Previously known as AbtAssociates Clinical Trials, the company was renamed Abt Bio-Pharma Solutionsand established as a wholly owned subsidiary of Abt Associates in April 2008.

SOURCE Abt Bio-Pharma Solutions, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Central Texas Health Care Provider Develops Instru...
S
Engineering a Solution to America's Health Care Wo...